Amgen, Cytokinetics And Servier Announce Start Of METEORIC-HF, The Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure
Go back to Amgen, Cytokinetics And Servier Announce Start Of METEORIC-HF, The Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure| Amgen Inc (NASDAQ: AMGN) | Delayed: 385.65 +5.87 (1.55%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $379.78 | 52 Week High | $176.85 | |||
| Open | $378.51 | 52 Week Low | $133.64 | |||
| Day High | $386.50 | P/E | 58.08 | |||
| Day Low | $378.51 | EPS | $6.64 | |||
| Volume | 8,528,108 | |||||
| CYTOKINETICS (NASDAQ: CYTK) | Delayed: 68.78 -1.14 (1.63%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $69.92 | 52 Week High | $13.18 | |||
| Open | $70.18 | 52 Week Low | $6.00 | |||
| Day High | $70.18 | P/E | N/A | |||
| Day Low | $68.15 | EPS | $-1.24 | |||
| Volume | 4,872,971 | |||||
